SmithKline Beecham
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare
GSK Headquarters Returns to Central London
GSK, Global Headquarters, Central London, The Earnshaw, Sustainability, Hybrid Working
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply
Gilead’s Twice-Yearly PrEP Drug Achieves 100% Efficacy in HIV Prevention
Gilead, PrEP, HIV prevention, lenacapavir, GSK, Apretude, HIV vaccine, HIV treatment
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy
GSK Acquires Oligonucleotide Partner Elsie for Up to $50 Million
GSK, Elsie Biotechnologies, oligonucleotide platform, acquisition, biotech, pharmaceuticals
GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment
Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate
Delaware Court Ruling Allows Zantac Lawsuits to Proceed, GSK Market Cap Plummets by Over $8 Billion
Zantac lawsuits, GSK market cap, Delaware court, pharmaceutical industry, legal battles, financial impact